X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

PAREXEL Co-Founder and Board Chairman Josef von Rickenbach Receives 2018 Ellis Island Medal of Honor

Content Team by Content Team
15th May 2018
in Americas, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, announced that Josef von Rickenbach, PAREXEL co-founder and Chairman of the Board of Directors, is the recipient of a 2018 Ellis Island Medal of Honor from the Ellis Island Honors Society (EIHS). Mr. von Rickenbach was honored with the recognition at a ceremony on Ellis Island on May 12.

The Ellis Island Medals of Honor are presented annually to a select group of individuals whose accomplishments in their field and inspired service to our nation are cause for celebration. The honor recognizes individuals who have made it their mission to share their wealth of knowledge, indomitable courage, boundless compassion, unique talents and selfless generosity with those less fortunate. The Medal has been officially recognized by both Houses of Congress as one of our nation’s most prestigious awards and is annually memorialized in the Congressional Record. Past Ellis Island Medal of Honor recipients include seven Presidents of the United States, Vice-President Joe Biden, Supreme Court Justice Sandra Day O’Connor and several Nobel laureates.

“I have always had a strong belief in both the great opportunities that exist in America, and the need to understand and respect the global environment in which we live and work. As such, I am deeply honored to receive an Ellis Island Medal of Honor from the Ellis Island Honors Society,” Mr. von Rickenbach said. “This prestigious recognition symbolizes the great diversity, integrity, passion and courage of America, all fundamental values that PAREXEL was built on, and I am truly humbled to be recognized among this remarkable list of honorees.”

A native of Switzerland, Mr. von Rickenbach co-founded PAREXEL in 1982 and retired as CEO earlier this year. During his tenure, he led the company’s approximately 18,000 employees to meaningfully contribute to 99 percent of the 200 top-selling biopharmaceuticals in the world today, products that help address patient needs in oncology, neurology, infectious disease, and countless other disease conditions. Mr. von Rickenbach became a U.S. citizen in 2002.

“Now more than ever it’s vital we recognize, celebrate, and embrace the diversity and backgrounds of all of the Americans who enrich and build upon the foundation of this great country,” said Nasser J. Kazeminy, Chairman of EIHS. “At the Ellis Island Honors Society, we want to focus on the future by honoring our past and present and with the Ellis Island Medals of Honor, we’re recognizing leaders and everyday heroes who are making a positive impact in order to build a better, brighter future for all Americans.”

In addition to the Ellis Island Medal of Honor, Mr. von Rickenbach was recently recognized by Informa’s Pharma Intelligence, receiving the Lifetime Achievement Award at the Clinical and Research Excellence Awards. He was also an Honoree at the Evening of Hope event benefitting the Biomedical Science Careers Program (BSCP), a non-profit organization that provides students of every race, ethnic background, gender and financial status with encouragement, support and guidance needed for the successful pursuit of biomedical science and other science-related careers.

About PAREXEL International
PAREXEL International Corporation is the world’s leading innovator of biopharmaceutical services. We simplify our clients’ journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world. For more information, visit www.PAREXEL.com.

Previous Post

Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition

Next Post

HDA's Pharmaceutical Cargo Security Coalition Recognizes Leaders for Commitment to a Safe and Secure Supply Chain

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

HDA's Pharmaceutical Cargo Security Coalition Recognizes Leaders for Commitment to a Safe and Secure Supply Chain

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In